
According to Benzinga Pro, during Q4, Syndax Pharmaceuticals (NASDAQ:SNDX) earned $96.20 million, a 566.1% increase from the preceding quarter. Syndax Pharmaceuticals also posted a total of $126.58 million in sales, a 922.84% increase since Q3. Syndax Pharmaceuticals collected $12.38 million in revenue during Q3, but reported earnings showed a $20.64 million loss.